IM
IMRX.US Immuneering Corp
- Market cap
- USD 240M
- P/E
- -
- P/B
- 1.42x
- ROE
- -43.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IMRX.US undervalued?
Graham numberThe Graham number of Immuneering Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Immuneering Corp fundamental analysis
No fundamental analysis for Immuneering Corp yet.
Immuneering Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Immuneering Corp
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and mul…
Full company profileImmuneering Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Immuneering Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1.92M | 2.31M | 2.08M | 317K | 455.00 | 0.00 | 0.00 | 481K |
| Gross Profit | 697K | 1.03M | 927K | 159K | -764K | -713K | -699K | -253K |
| Operating Income | -6.29M | -17.1M | -33.9M | -51.7M | -58.4M | -64.1M | -59.4M | -80.2M |
| EBITDA | -7.34M | -17.0M | -33.7M | -51.5M | -58.1M | -63.7M | -55.7M | -77.4M |
| Net Income | -7.71M | -17.0M | -33.5M | -50.5M | -53.5M | -61.0M | -56.0M | -73.2M |
| EPS | -0.57 | -1.26 | -1.27 | -1.91 | -1.88 | -2.04 | -1.27 | -1.13 |
| Balance Sheet | ||||||||
| Total Assets | 14.1M | 38.4M | 167M | 122M | 103M | 52.7M | 232M | 183M |
| Total Liabilities | 20.6M | 60.9M | 10.7M | 12.5M | 12.0M | 11.3M | 13.5M | 13.9M |
| Shareholders' Equity | -6.53M | -22.5M | 156M | 110M | 90.6M | 41.4M | 218M | 169M |
| Cash & Short-term Investments | 13.8M | 37.1M | 149M | 106M | 85.7M | 36.1M | 173M | 145M |
| Total Debt | 16.6M | 621K | 5.36M | 4.84M | 4.46M | 4.16M | 3.82M | 3.53M |
| Cash Flow | ||||||||
| Operating Cash Flow | -4.44M | -14.6M | -30.9M | -44.1M | -49.0M | -55.0M | -45.3M | -69.0M |
| Capital Expenditure | 20.5K | 53.4K | 60.8K | 742K | 343K | 84.9K | 142K | 163K |
| Free Cash Flow | -4.46M | -14.7M | -30.9M | -44.8M | -49.3M | -55.1M | -45.5M | -69.1M |
| Ratios | ||||||||
| ROE | - | - | -21.5% | -46.0% | -59.0% | -147.5% | -25.6% | -43.4% |
| ROA | -54.7% | -44.3% | -20.1% | -41.3% | -52.1% | -115.8% | -24.2% | -40.1% |
| Net Profit Margin | -401.6% | -737.2% | -1,612.3% | -15,937.3% | -11,752,004.8% | - | - | -15,216.1% |
| Debt to Equity | - | - | 0.03x | 0.04x | 0.05x | 0.10x | 0.02x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Immuneering Corp dividends
Immuneering Corp has not paid dividends in the last 7 fiscal years.
Who owns Immuneering Corp
- Insiders 14.24%
- Institutions 58.04%
- Public & others 27.73%
- Shares outstanding 64.8M
- Free float 49.3M
Top funds holding IMRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HBM Healthcare Investments AG Ord | 3.65M | 5.63% | 0.00% | Sep 2026 |
| Fidelity Growth Company Fund | 2.94M | 4.54% | 0.00% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.62M | 2.51% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.38M | 2.14% | 0.00% | Oct 2026 |
| Fidelity Select Biotechnology | 1.10M | 1.69% | 0.00% | Aug 2026 |
| Fidelity Growth Company K6 | 832K | 1.28% | 0.00% | Aug 2026 |
| abrdn Healthcare Investors | 785K | 1.21% | 0.00% | Oct 2026 |
| Fidelity Series Growth Company | 720K | 1.11% | 0.00% | Aug 2026 |
| Fidelity Small Cap Index | 594K | 0.92% | +1.70% | Aug 2026 |
| iShares Russell 2000 Value ETF | 528K | 0.82% | 0.00% | Oct 2026 |
| CREF Total Global Stock Account R3 | 467K | 0.72% | +200.56% | Sep 2026 |
| iShares Biotechnology ETF | 449K | 0.69% | -0.19% | Oct 2026 |
| Nuveen Equity Index R6 | 330K | 0.51% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 329K | 0.51% | +7.19% | Sep 2026 |
| Fidelity Extended Market Index | 261K | 0.40% | -5.60% | Sep 2026 |
| iShares Micro-Cap ETF | 170K | 0.26% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 139K | 0.21% | +6.35% | Sep 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 104K | 0.16% | -5.89% | Oct 2026 |
| Fidelity Total Market Index | 103K | 0.16% | -0.05% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 100K | 0.15% | 0.00% | Sep 2026 |
Top institutions holding IMRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 9.70M | 14.98% | +0.07% | Jun 2026 |
| BlackRock Inc | 4.37M | 6.75% | +190.20% | Jun 2026 |
| Sanofi | 2.71M | 4.18% | 0.00% | Sep 2026 |
| Vanguard Capital Management, LLC | 2.29M | 3.53% | -0.08% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.94M | 2.99% | +5.84% | Jun 2026 |
| Geode Capital Management, LLC | 1.37M | 2.12% | +114.87% | Jun 2026 |
| State Street Corp | 1.00M | 1.55% | +273.15% | Jun 2026 |
| DCF Advisers, LLC | 790K | 1.22% | +458.45% | Jun 2026 |
| Aberdeen Group PLC | 785K | 1.21% | 0.00% | Sep 2026 |
| Marshall Wace Asset Management Ltd | 732K | 1.13% | -63.34% | Jun 2026 |
| Connor Clark & Lunn Inv Mgmt Ltd | 601K | 0.93% | +50.18% | Jun 2026 |
| Alethea Capital Management, LLC | 473K | 0.73% | +1,962.07% | Jun 2026 |
| Summit Financial LLC | 452K | 0.70% | +20.04% | Jun 2026 |
| UBS Group AG | 449K | 0.69% | +19.29% | Jun 2026 |
| Nuveen, LLC | 438K | 0.68% | 0.00% | Jun 2026 |
| Northern Trust Corp | 437K | 0.67% | +271.38% | Jun 2026 |
| Citadel Advisors Llc | 386K | 0.60% | -13.61% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 361K | 0.56% | +12.03% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 359K | 0.55% | 0.00% | Jun 2026 |
| GSA Capital Partners LLP | 343K | 0.53% | +347.29% | Jun 2026 |
Immuneering Corp company profile
- Company name
- Immuneering Corp
- Ticker
- IMRX.US
- Exchange
- USA Stocks
- Listed since
- Jul 30, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 65
- Fiscal year end
- December
- Address
- 245 Main Street, Cambridge, MA, United States, 02142
- Phone
- 617 500 8080
- Website
- immuneering.com
About Immuneering Corp
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Immuneering Corp management
10- Dr. Benjamin J. Zeskind M.B.A., Ph.D.Co-Founder, President, CEO & Director · born 1983
- Mr. Robert J. Carpenter M.B.A., M.S.Co-Founder & Chair Emeritus · born 1946
- Dr. Brett M. Hall Ph.D.Chief Scientific Officer · born 1969
- Mr. Michael D. Bookman J.D.Chief Legal Officer & Secretary · born 1987
- Mr. Andrew W. GengosCFO & Treasurer · born 1964
- Ms. Paula George CPASenior Director of Accounting & Operations and Assistant Corporate Controller
- Ms. Mallory Morales CPASenior VP of Finance, Chief Accounting Officer & Assistant Treasurer · born 1983
- Ms. Jyoti JoshiDirector of Quality Systems & Compliance
- Mr. David CaouetteVice President of Corporate Communications
- Ms. Leah R. NeufeldChief People Officer · born 1972